32 results about "Dyslipidemia" patented technology

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, e.g., siRNAs, capable of inhibiting expression of the subunit beta E (INHBE) gene. Also disclosed are pharmaceutical compositions comprising the INHBE RNAi agents, and methods of use thereof. The INHBE RNAi agents disclosed herein can be conjugated to targeting ligands to facilitate delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agent in vivo results in inhibition of expression of the INHBE gene. RNAi agents may be used in methods of treating diseases, disorders, or conditions mediated in part by the expression of the INHBE gene, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic diseases.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and / or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and / or other SCAP-associated conditions, diseases, and / or disorders.

The present invention relates to a dual-targeting siRNA agent comprising two distinct siRNAs targeting two different genes or their pharmaceutically acceptable salts, wherein the two distinct siRNAs or their salts are linked by a pharmaceutically acceptable ligand. The siRNA is a dsRNA composed of a sense strand and an antisense strand, and the two different genes are selected from a group consisting of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9), and human angiopoietin-like protein 3 (ANGPTL3). The present invention provides the application of the dual-targeting siRNA agent in the preparation of drugs for preventing or treating diseases associated with hypertension and / or dyslipidemia. The dual-targeting siRNA agent described in the present invention can effectively inhibit the expression of two target genes simultaneously in vivo, offering the advantages of strong non-antagonistic activity and high safety. The present invention also provides the siRNAs targeting corresponding genes for the aforementioned dual-targeting siRNA agent and their use for preventing or treating diseases associated with hypertension and / or dyslipidemia.

The invention relates to the technical field of coreopsis tinctoria refined components and preparation and application, and provides a coreopsis tinctoria refined component and a preparation method and application thereof.The coreopsis tinctoria refined component comprises, by mass, 11 specific components of phenolic acids, flavonol, flavanol and flavonoid, and the 11 specific components comprise, by mass, 2 parts of gallic acid, 1 part of potassium sorbate, 1 part of potassium sorbate, 1 part of potassium sorbate and 1 part of potassium sorbate. The health-care food is prepared from the following raw materials in parts by weight: 3 parts of chlorogenic acid, 14 parts of quercetin, 18 parts of catechin, 5 parts of citric acid, 2-3 parts of procyanidine B, 3 parts of (+)-epicatechin, 1-31 parts of 31 parts of procyanidine C, 14 parts of rutin, 4 parts of camphanol-3-O-rutinoside and 2 parts of isorhamnetin-3-O-rutinoside. The snow chrysanthemum is Changbai Mountain snow chrysanthemum. Animal experiments show that the refined component can significantly reduce the content of total cholesterol and triglyceride in serum of a high-fat model rat, the specific component with blood fat regulating activity is prepared from Changbai Mountain snow chrysanthemum, and a new choice is provided for non-drug intervention of dyslipidemia.

The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

The application discloses a dyslipidemia risk prediction device and terminal equipment, method and storage medium, and relates to the technical field of medical detection equipment. The device comprises an acquisition module, a first processing module and a second processing module which are connected with each other. The first processing module is used for inputting SNP genotype data of a to-be-predicted object into a pre-constructed scoring model, obtaining a polygenic risk score, and inputting an actual age and a phenotype age into a pre-constructed age linear regression model after obtaining the phenotype age based on clinical biochemical marker data and the actual age of the to-be-predicted object, so as to obtain a phenotype age acceleration value. The second processing module is used for inputting the polygenic risk score, the phenotype age acceleration value and individual characteristic data into a pre-constructed integrated model, obtaining a prediction result set, and taking a mode of the prediction result set as a prediction result of the to-be-predicted object. The device can be used for more comprehensive and accurate prediction and can improve processing efficiency.

This invention discloses a composition for improving metabolic syndrome, its preparation method, and its application. The composition for improving metabolic syndrome comprises privet fruit, honeysuckle, wolfberry fruit, kudzu root, and astragalus root. The medicinal materials used in the formulation involved in this invention are all traditional Chinese medicinal herbs that are also used in food, exhibiting extremely high safety and definite efficacy. two and db In mice, it demonstrated clear efficacy in lowering blood sugar and improving metabolic syndrome, comparable to metformin, and even superior to metformin in some lipid parameters. Further mechanistic studies showed that the optimized formulation 3 can exert a synergistic effect by regulating multiple metabolic pathways, and can be used to regulate metabolic-related diseases such as diabetes, fatty liver, alcoholic liver disease, and dyslipidemia.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

GLP-1-Fc-FGF21 double-target fusion protein composition and its use. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by adding the buffer solution, the formation of visible particles can be effectively controlled, the stability of the GLP-1-Fc-FGF21 fusion protein can be improved, and the shelf life of the product can be extended. The composition can be used to treat and / or prevent metabolic diseases such as diabetes, dyslipidemia, obesity, and diseases associated with fatty liver.

The present application relates to the field of biological medicine and functional food, and discloses a kind of nutrition composition based on marine shrimp peptide for anti-obesity and improving metabolic syndrome;Including: Chinese tube whip shrimp peptide active component and pharmaceutically acceptable adjuvant, the Chinese tube whip shrimp meat protein is used as raw material, and the Chinese tube whip shrimp meat protein is prepared by alkaline protease enzymolysis, and the Chinese tube whip shrimp meat protein contains peptide segment with molecular weight less than 1 kDa, and APPPPP, HPPPP and MPLPP can be detected.The pharmaceutical composition can reduce the weight and fat tissue weight under the state of obesity, improve dyslipidemia, abnormal liver function and liver steatosis, reduce oxidative stress level, improve intestinal mucosal barrier damage and intestinal permeability increase, and regulate intestinal flora structure change.The active component in the present application is clear in origin, and the preparation process is clear, has the synergistic effect from lipid metabolism regulation, liver protection to intestinal barrier improvement, and can be used for preparing medicine for preventing or treating obesity and improving metabolic syndrome.

The present application provides novel long-acting Amylin receptor agonists and uses thereof. The Amylin receptor agonists are prepared by solid phase synthesis and / or solution phase synthesis, cleavage of the peptide resin, formation of a disulfide bond between the thiol groups of Cys2 and Cys7, RCM ring closure of the side chains of AA2 and AA7 double bond, hydrogenation, and optional isolation and purification. The compounds disclosed herein can be used in combination with one or more additional therapeutic agents for the treatment of diabetes and its complications, obesity and its complications, dyslipidemia, hypertension, OSA, and / or NASH, either simultaneously, separately or sequentially.

The application discloses application of 1,5-dicaffeoylquinic acid in prevention and / or treatment of non-alcoholic fatty liver disease and weight loss and blood lipid reduction, and belongs to the technical field of biological medicine. The application first proposes application of 1,5-dicaffeoylquinic acid in preparation of a medicine for preventing and / or treating metabolic related fatty diseases. In-vivo and in-vitro experimental results show that after 1,5-dicaffeoylquinic acid is used in an in-vitro and in-vivo NAFLD model, the weight can be reduced, liver function and blood lipid abnormality, sugar metabolism abnormality and lipid accumulation can be relieved; the 1,5-dicaffeoylquinic acid can be used for preparing a medicine for preventing or treating NAFLD, obesity and blood lipid reduction, and the new use of the 1,5-dicaffeoylquinic acid in resisting NAFLD is confirmed, so that the 1,5-dicaffeoylquinic acid is expected to be developed into a new type of NAFLD resisting medicine, and has a wide market prospect.

The invention is concerned with a bacterium comprising a phytate to 3-hydroxoypropionate pathway gene set that allows said bacterium to convert phytate to 3-hydroxypropionate or a salt or ester thereof. The bacterium can be used as a probiotic or supplement to promote production of propionate in the Gl tract, thereby preventing and / or treating conditions or diseases that benefit from the production of propionate, for example metabolic disease, metabolic syndrome, obesity, insulin resistance or insulin resistance-related conditions, particularly dyslipidemia, (M)ASLD-(M)ASH, type 2 diabetes mellitus and insulin-resistance in endocrine diseases.

The present application relates to the field of medicine synthesis, disclose a long-acting dual agonist compound. The tirzepatide derivative described in the application is used for preparing a pharmaceutical composition for treating diseases, the use of the pharmaceutical composition in the preparation of a medicine for treating at least one of the following diseases, the diseases include type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or indigestion or gastric ulcer, liver fibrosis disease and pulmonary fibrosis disease.

This disclosure provides GLP-1 / GIP and GLP-1 / GCG dual receptor agonists comprising incretin analog polypeptides, as well as their use in the treatment or prevention of type 2 diabetes mellitus (T2DM), hyperlipidemia / dyslipidemia, metabolic syndrome, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risk, and / or obesity.

The application discloses STUB1 application of the gene or the STUB1 protein coded by the gene in the preparation of a medicine for preventing or treating obesity and related metabolic diseases STUB1 The application first proves that the gene and the coded protein are key target points for regulating fat metabolism, and the bidirectional regulation value is determined: on one hand, inhibition of STUB1 can significantly up-regulate the CIDEC protein level, promote normal fat storage of adipocytes, and improve insulin resistance and non-alcoholic fatty liver disease; on the other hand, activation of STUB1 can accelerate the degradation of CIDEC, inhibit lipid storage, realize the effect of reducing fat, and provide a brand-new intervention target point and treatment idea for metabolic diseases such as obesity, type 2 diabetes and dyslipidemia.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), NAFL, NASH, dyslipidemia, and related disorders thereto.

The present disclosure relates to combinations of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of a fixed dose combination product, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The present invention relates to compositions comprising microorganisms for use in reducing blood urate concentration. These compositions can be used in the therapeutic and prophylactic treatment of subjects at risk of, or suffering from, elevated blood urate levels. The compositions can be pharmaceutical or nutraceutical compositions for the treatment and prevention of urate and hyperuricemia related diseases such as cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease, gout, insulin resistance, hypertension, dyslipidemia, renal insufficiency, obesity, prediabetes and diabetes.

The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and / or treatment of diseases which are associated with the modulation of LXR, for example, dyslipidemias. The present disclosure further relates to the use of the present compounds in the prophylaxis and / or treatment of metabolic disorders associated with an impairment in lipid homeostasis.

The present disclosure provides an siRNA for inhibiting the expression of angiopoietin-like protein 3 gene, a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, the siRNA contains a sense strand and an antisense strand, the sense strand contains a nucleotide sequence I, the nucleotide sequence I is equal in length to the nucleotide sequence shown in SEQ ID NO: 1, and differs by no more than 3 nucleotides, and the antisense strand contains a nucleotide sequence II, the nucleotide sequence II is equal in length to the nucleotide sequence shown in SEQ ID NO: 2, and differs by no more than 3 nucleotides. The siRNA, and the pharmaceutical composition and conjugate thereof provided by the present disclosure can effectively treat and / or prevent dyslipidemia.

The present invention relates to GLP-1 / GIP / GCG triple receptor agonists and their use in the treatment or prevention of type 2 diabetes mellitus (T2DM), hyperlipidemia / dyslipidemia, metabolic syndromes, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risk, and / or obesity.

This invention discloses a sea buckthorn compound composition, sea buckthorn compound active ingredients, sea buckthorn compound preparations, their preparation methods, and applications. The sea buckthorn compound composition, by weight, comprises the following components: 20-26 parts sea buckthorn, 17-21 parts kelp, 9-11 parts chuanxiong rhizome, 9-11 parts astragalus root, 9-11 parts notoginseng, 7-9 parts earthworm, 7-9 parts scutellaria baicalensis, 7-9 parts cassia seed, 3-5 parts hawthorn, and 3-5 parts chrysanthemum. The sea buckthorn compound active ingredients and sea buckthorn compound preparations obtained from the sea buckthorn compound composition of this invention exhibit excellent stability and pharmacodynamic properties, can improve vascular condition or blood lipid levels, and are suitable for treating various diseases related to arterial plaque, dyslipidemia, vascular wall thickening, or vascular endothelial inflammation.